Stockscreener 앱 받기
2.28
4.59%
0.10
전일 마감가:
$2.18
열려 있는:
$2.17
하루 거래량:
475.53K
Relative Volume:
1.19
시가총액:
$289.74M
수익:
-
순이익/손실:
$-57.09M
주가수익비율:
-5.0476
EPS:
-0.4517
순현금흐름:
$-51.43M
1주 성능:
-0.22%
1개월 성능:
-3.39%
6개월 성능:
+17.53%
1년 성능:
+222.03%
1일 변동 폭
$2.1101
$2.28
1주일 범위
$2.1101
$2.355
52주 변동 폭
$0.62
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
명칭
Nautilus Biotechnology Inc
전화
206-333-2001
주소
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.28 | 289.74M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-06-27 | 개시 | Guggenheim | Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2022-01-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-02 | 개시 | Cowen | Outperform |
| 2021-08-04 | 개시 | Goldman | Neutral |
| 2021-07-13 | 개시 | Jefferies | Buy |
모두보기
Nautilus Biotechnology Inc 주식(NAUT)의 최신 뉴스
Nautilus Biotech stockholders approve directors and governance items - TipRanks
Nautilus Biotechnology (NAUT) investors approve directors, auditor and annual Say on Pay - Stock Titan
Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nautilus Biotechnology Inc (NAUT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nautilus Biotechnology Inc (NAUT) Institutional Confidence - TradingKey
Nautilus Biotechnology Inc (NAUT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nautilus Biotechnology Inc (NAUT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nautilus Biotechnology Inc (NAUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nautilus Biotechnology Inc (NAUT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nautilus Biotechnology Inc (NAUT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nautilus Biotechnology (NAUT) Slides 2.67% as Shares Test Key Support ZoneETF AUM Growth - newsline.com
Nautilus Biotechnology Inc (NAUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nautilus Biotechnology (NAUT) Holds Near Support After Modest UptickETF Outflow Streak - newsline.com
Nautilus Biotechnology (NAUT) Shows Modest Gains Amid Tight Trading RangeNaked POC - newsline.com
Nautilus Biotechnology (NAUT) Edges Higher Amid Biotech Sector Gains; Resistance Test in FocusForce Index - newsline.com
Nautilus Biotechnology (NAUT) Plunges 10.8% as Bearish Momentum BuildsLow Risk Entry Stocks - newsline.com
NAUT Stock Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Tau proteoform quantification research unveiled by Nautilus Biotechnology at ASMS2026 - Traders Union
Andreessen Horowitz (NAUT) funds sell 5M shares, retain near-10% stake - Stock Titan
Andreessen Horowitz funds trim Nautilus (NAUT) stake with 5M-share open-market sale - Stock Titan
Nautilus Biotechnology | 4: Statement of changes in beneficial ownership of securities-10% Owner AH Equity Partners Bio II, L.L.C.moomoo - Moomoo
Nautilus Biotechnology promotes single molecule proteomics at ASMS with Voyager platform experts - Traders Union
NAUT News | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Surges 5.4% as Biotech Sector Momentum BuildsIntraday Profile - The Legal Advocate
Nautilus Biotechnology (NAUT) Surges Over 5% as Small-Cap Biotech Shows Renewed StrengthMoney Flow - newsline.com
NAUT Q1 2026 Earnings: Narrowed Losses Beat Estimates Amid Platform ProgressEPS Miss Report - The Legal Advocate
Nautilus Biotechnology (NAUT) Pulls Back: Key Levels to Watch After 3.9% DeclineEnding Diagonal - The Legal Advocate
Nautilus Biotechnology (NAUT) Holds Steady at $2.54 as Stock Consolidates Near Key LevelsLow Volatility Picks - Newser
NAUT Stock Price, Quote & Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Q1 2026 Earnings Surprise: EPS $-0.12, Up SignificantStock Analysis Community - Newser
Nautilus Biotechnology Decline Means Insider Profits Down To US$432k - Moomoo
Nautilus Biotechnology introduces Voyager Platform for precise tau proteoform analysis - Traders Union
TradingKey - TradingKey
Nautilus Biotechnology unveils Voyager Platform for quantifying 768 tau proteoforms at Tau Global 2026 - Traders Union
NAUT (Nautilus Biotechnology) quarterly results under review as market awaits full earnings disclosure and segment analysis.Social Buzz Stocks - Newser
Why Nautilus Biotechnology (NAUT) ability to execute stands out (Market Focus) 2026-05-06Fibonacci Fan - thelegaladvocate.com
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Nautilus Biotechnology (NAUT) price target increased by 60.00% to 4.08 - MSN
Nautilus expects cash runway through 2027 while targeting oncology early access in H2 2026 - MSN
What revision trend Nautilus Biotechnology (NAUT)? (Spikes) 2026-05-01Percent Above MA - newsline.com
Guggenheim Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Nautilus Biotechnology (NAUT) outlines 2026 shareholder votes on directors, pay and auditor - Stock Titan
Nautilus Biotechnology (NASDAQ: NAUT) details Q1 2026 loss and cash runway - Stock Titan
Nautilus Biotechnology Plans Voyager Platform Launch for Late 2026 - HarianBasis.co
Nautilus Biotechnology Q1 Earnings Call Highlights - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Nautilus Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Nautilus Biotechnology Reports First Quarter 2026 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast - Investing.com
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast By Investing.com - Investing.com Canada
Nautilus Biotechnology Inc (NAUT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):